Group One Trading’s Pacific Biosciences PACB Stock Holding History

Group One Trading’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$113K	Sell	85,800 -910,300	-91%	-$1.63M	﹤0.01%	4617
2025 Q4	$1.86M	Buy	996,100 +225,600	+29%	+$434K	﹤0.01%	2342
2025 Q3	$986K	Buy	770,500 +94,800	+14%	+$128K	﹤0.01%	3044
2025 Q2	$838K	Sell	675,700 -557,400	-45%	-$644K	﹤0.01%	2929
2025 Q1	$1.46M	Buy	1,233,100 +814,100	+194%	+$1.25M	﹤0.01%	2115
2024 Q4	$767K	Sell	419,000 -406,200	-49%	-$793K	﹤0.01%	2803
2024 Q3	$1.4M	Buy	825,200 +592,200	+254%	+$973K	﹤0.01%	2013
2024 Q2	$319K	Buy	233,000 +20,300	+10%	+$41K	﹤0.01%	2980
2024 Q1	$798K	Sell	212,700 -107,300	-34%	-$628K	﹤0.01%	2289
2023 Q4	$3.14M	Buy	320,000 +40,600	+15%	+$332K	0.01%	1490
2023 Q3	$2.33M	Sell	279,400 -800	-0.3%	-$9.14K	0.01%	1518
2023 Q2	$3.73M	Sell	280,200 -4,300	-2%	-$52.3K	0.01%	1192
2023 Q1	$3.29M	Sell	284,500 -453,800	-61%	-$4.51M	0.01%	1125
2022 Q4	$6.04M	Buy	738,300 +283,800	+62%	+$2.45M	0.01%	1030
2022 Q3	$2.64M	Buy	454,500 +86,500	+24%	+$496K	0.01%	1668
2022 Q2	$1.63M	Sell	368,000 -345,500	-48%	-$2.1M	﹤0.01%	2246
2022 Q1	$6.49M	Buy	713,500 +619,600	+660%	+$7.13M	0.01%	1331
2021 Q4	$1.92M	Sell	93,900 -2,700	-3%	-$65.2K	﹤0.01%	2642
2021 Q3	$2.47M	Sell	96,600 -289,900	-75%	-$8.59M	﹤0.01%	2437
2021 Q2	$13.5M	Sell	386,500 -406,900	-51%	-$11.8M	0.02%	868
2021 Q1	$26.4M	Buy	793,400 +523,000	+193%	+$18.3M	0.04%	415
2020 Q4	$7.01M	Buy	270,400 +133,800	+98%	+$2.27M	0.01%	1046
2020 Q3	$1.35M	Buy	136,600 +76,800	+128%	+$442K	﹤0.01%	1925
2020 Q2	$206K	Buy	59,800 +9,200	+18%	+$31.3K	﹤0.01%	3355
2020 Q1	$155K	Buy	50,600 +15,800	+45%	+$64.7K	﹤0.01%	2953
2019 Q4	$179K	Buy	34,800 +28,100	+419%	+$143K	﹤0.01%	3257
2019 Q3	$35K	Sell	6,700 -56,100	-89%	-$314K	﹤0.01%	4144
2019 Q2	$380K	Sell	62,800 -16,300	-21%	-$114K	﹤0.01%	2387
2019 Q1	$572K	Buy	79,100 +33,700	+74%	+$244K	0.01%	1838
2018 Q4	$336K	Buy	45,400 +43,400	+2,170%	+$275K	﹤0.01%	2283
2018 Q3	$11K	Buy	+2,000	New	+$8.58K	﹤0.01%	4625
2018 Q1	–	Sell	-6,200	Closed	-$16K	–	5194
2017 Q4	$16K	Sell	6,200 -20,500	-77%	-$71.8K	﹤0.01%	4227
2017 Q3	$140K	Buy	+26,700	New	+$115K	﹤0.01%	3007
2017 Q2	–	Sell	-19,200	Closed	-$99K	–	4984
2017 Q1	$99K	Buy	19,200 +16,000	+500%	+$78.3K	﹤0.01%	2993
2016 Q4	$12K	Sell	3,200 -56,100	-95%	-$408K	﹤0.01%	3895
2016 Q3	$531K	Sell	59,300 -59,900	-50%	-$501K	0.01%	1774
2016 Q2	$839K	Buy	119,200 +27,000	+29%	+$247K	0.01%	1369
2016 Q1	$784K	Buy	92,200 +19,500	+27%	+$192K	0.01%	1355
2015 Q4	$955K	Buy	72,700 +22,700	+45%	+$204K	0.01%	1346
2015 Q3	$183K	Buy	50,000 +49,600	+12,400%	+$242K	﹤0.01%	2568
2015 Q2	$2K	Hold	400	–	–	﹤0.01%	4672
2015 Q1	$2K	Sell	400 -1,500	-79%	-$10.3K	﹤0.01%	4571
2014 Q4	$15K	Sell	1,900 -7,000	-79%	-$44.8K	﹤0.01%	4081
2014 Q3	$44K	Sell	8,900 -25,100	-74%	-$131K	﹤0.01%	3608
2014 Q2	$210K	Sell	34,000 -3,400	-9%	-$17K	﹤0.01%	2363
2014 Q1	$200K	Buy	37,400 +30,700	+458%	+$194K	﹤0.01%	2446
2013 Q4	$35K	Sell	6,700 -12,400	-65%	-$56.9K	﹤0.01%	3889
2013 Q3	$106K	Buy	19,100 +3,000	+19%	+$10.4K	﹤0.01%	2973
2013 Q2	$41K	Buy	+16,100	New	+$40.1K	﹤0.01%	3599

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Group One Trading's PACB Position: Q1 2026 in Review

Group One Trading reduced its Pacific Biosciences (PACB) stake by 21% in Q1 2026, selling an estimated $170K and leaving 365,021 shares worth $482K. The position accounts for ﹤0.01% of the portfolio, ranked #3382.

Group One Trading first reported a position in PACB in Q2 2013 and has held it in 42 quarters since. The position peaked at $7.36M in Q4 2020. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

Group One Trading held 365,021 shares of Pacific Biosciences worth $482K as of Q1 2026.
Group One Trading sold 95,229 Pacific Biosciences shares in Q1 2026, an estimated $170K.
Pacific Biosciences made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #3382 holding.
Group One Trading first reported a position in Pacific Biosciences in Q2 2013 and has held it in 42 quarters since.
Group One Trading's Pacific Biosciences position peaked at $7.36M in Q4 2020.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.